Interest in and Preference for Long-acting Injectable Antiretroviral Therapy in the Era of Approved Cabotegravir/Rilpivirine among Reproductive-aged Women in the U.S. South

Lauren F Collins; Anandi N Sheth; Tina Tisdale; C Christina Mehta; Gaea Daniel; Daniel Westreich; Seble Kassaye; Elizabeth F Topper; Deborah Konkle-Parker; Aadia Rana; Maria L Alcaide; Morgan M Philbin

doi:10.1093/cid/ciae331

Interest in and Preference for Long-acting Injectable Antiretroviral Therapy in the Era of Approved Cabotegravir/Rilpivirine among Reproductive-aged Women in the U.S. South

Clin Infect Dis. 2024 Jun 29:ciae331. doi: 10.1093/cid/ciae331. Online ahead of print.

Authors

Lauren F Collins^{1

2}, Anandi N Sheth^{1

2}, Tina Tisdale^{1

2}, C Christina Mehta¹, Gaea Daniel³, Daniel Westreich⁴, Seble Kassaye⁵, Elizabeth F Topper⁶, Deborah Konkle-Parker⁷, Aadia Rana⁸, Maria L Alcaide⁹, Morgan M Philbin¹⁰

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
² Ponce de Leon Center, Grady Health System, Atlanta, GA, USA.
³ Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA, USA.
⁴ Department of Epidemiology, University of North Carolina-Chapel Hill, NC, USA.
⁵ Department of Medicine, Georgetown University, Washington, D.C., USA.
⁶ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
⁷ Schools of Nursing, Medicine, and Population Health Sciences, University of Mississippi Medical Center, Jackson, MS, USA.
⁸ Division of Infectious Diseases, Department of Medicine, University of Alabama-Birmingham Heersink School of Medicine, Birmingham, AL, USA.
⁹ Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
¹⁰ Division of Vulnerable Populations, Department of Medicine, University of California San Francisco, San Francisco, California, USA.

PMID: 38943370
DOI: 10.1093/cid/ciae331

Abstract

Among 103 reproductive-aged women with HIV in the U.S. South surveyed post-approval of long-acting injectable (LAI) cabotegravir/rilpivirine, nearly two-thirds reported willingness to try LAI antiretroviral therapy (ART). Most expressed preference for LAI over daily oral ART and had minimal concerns over potential LAI-ART use impacting reproductive health.

Keywords: HIV and pregnancy; Southern HIV/AIDS epidemic; cabotegravir/rilpivirine; long-acting injectable antiretroviral therapy; women with HIV.

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Grants and funding

R01 HD101352/HD/NICHD NIH HHS/United States